Innovating the Fight Against Infection

At Telephus Biosciences, we are transforming the treatment of antibiotic-resistant infections with next-generation immunotherapies to improve patient outcomes worldwide.

Innovating the Fight Against Infection

At Telephus Biosciences, we are transforming the treatment of antibiotic-resistant infections with next-generation immunotherapies to improve patient outcomes worldwide.

Innovating the Fight Against Infection

At Telephus Biosciences, we are transforming the treatment of antibiotic-resistant infections with next-generation immunotherapies to improve patient outcomes worldwide.

Focus: MRSA Osteomyelitis

Our lead program, TPH 101, is a monoclonal antibody for the treatment of MRSA osteomyelitis. Osteomyelitis is a devastating bone infection caused by methicillin-resistant Staphylococcus aureus (MRSA) bacteria. This infection can arise from complications of orthopedic surgery (e.g., hip or knee replacement), from orthopedic trauma, or as a complication of diabetes.

The bone loss and tissue damage from these infections can be devastating, resulting in significant morbidity and mortality. With over one million joint replacement procedures performed in the U.S. every year, in addition to the seven million Americans currently living with hip and knee replacements, the need for new treatments to cure MRSA osteomyelitis has never been greater.

At Telephus, we are taking a new approach with TPH 101—a novel monoclonal antibody based on our proprietary immunotherapy platform that enhances the body’s immune system to better fight drug-resistant infections.

1 Million
Joint replacements performed in the U.S. annually
7 Million
Americans currently living with hip and knee replacements

Immunotherapy Platform

The current standard of care for MRSA osteomyelitis is long-term, high-dose vancomycin treatment plus adjunctive surgery. Despite this intensive treatment paradigm, 40% of MRSA osteomyelitis patients fail to completely clear their infections. Of the patients that survive these life-threatening infections, many must opt for amputation or definitive surgery to fuse the affected joint, while others must undergo repeated cycles of surgical revision and antibiotic therapy, often with serious side effects with devastating outcomes.

TPH 101 is modeled after a naturally-occurring high-titer antibody found in high-risk joint replacement patients who recover from MRSA bone infections despite their significant comorbidities.

TPH 101 is being developed to improve the treatment of MRSA osteomyelitis as an adjunctive therapy and has the potential to save the healthcare system billions of dollars.

Immunotherapy Platform

The current standard of care for MRSA osteomyelitis is long-term, high-dose vancomycin treatment plus adjunctive surgery. Despite this intensive treatment paradigm, 40% of MRSA osteomyelitis patients fail to completely clear their infections. Of the patients that survive these life-threatening infections, many must opt for amputation or definitive surgery to fuse the affected joint, while others must undergo repeated cycles of surgical revision and antibiotic therapy, often with serious side effects with devastating outcomes.

TPH 101 is modeled after a naturally-occurring high-titer antibody found in high-risk joint replacement patients who recover from MRSA bone infections despite their significant comorbidities.

TPH 101 is being developed to improve the treatment of MRSA osteomyelitis as an adjunctive therapy and has the potential to save the healthcare system billions of dollars.

Immunotherapy Platform

The current standard of care for MRSA osteomyelitis is long-term, high-dose vancomycin treatment plus adjunctive surgery. Despite this intensive treatment paradigm, 40% of MRSA osteomyelitis patients fail to completely clear their infections. Of the patients that survive these life-threatening infections, many must opt for amputation or definitive surgery to fuse the affected joint, while others must undergo repeated cycles of surgical revision and antibiotic therapy, often with serious side effects with devastating outcomes.

TPH 101 is modeled after a naturally-occurring high-titer antibody found in high-risk joint replacement patients who recover from MRSA bone infections despite their significant comorbidities.

TPH 101 is being developed to improve the treatment of MRSA osteomyelitis as an adjunctive therapy and has the potential to save the healthcare system billions of dollars.

Pipeline

At Telephus, we have built a therapeutics pipeline that leverages targeting of Autolysin A (AtlA) virulence factor that underlies much of the pathology of MRSA infection.

PipelinePipeline

Technology: Autolysin A Inhibitor

Autolysin A (AtlA) is a protein that drives cell wall division and biofilm production in MRSA bacteria. AtlA underlies much of the pathology of MRSA infection, promoting the rapid spread of infection and biofilm formation that allow MRSA bacteria to evade the immune system.

TPH 101 is a monoclonal antibody that neutralizes a key component of AtlA, inhibiting cell wall division and suppressing biofilm development, allowing a patient’s immune system to target MRSA bacteria that may persist despite high-dose vancomycin antibiotic therapy.